Previous studies (39,40,42,43) have shown that when HCT-116 cells were treated with celecoxib, a selective cyclooxygenase-2 inhibitor, Tcf-4 expression was significantly inhibited and Wnt/β-catenin and Tcf-4 expression was blocked, reducing human colon cancer cell proliferation (42). Here, PTGS2 is linked to colonic neoplasm.